VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | The safety and efficacy of peritransplantation ruxolitinib in patients with MF

Haris Ali, MD, City of Hope, Duarte, CA, discusses the safety and efficacy of peritransplantation ruxolitinib in patients with myelofibrosis (MF), highlighting the results from a pilot study which demonstrated that peritransplantation ruxolitinib is tolerable and reduces the risk of graft-versus-host disease (GvHD). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter